Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

HPV vaccination rates are low, especially in HIV prone populations

HPV vaccination rates in populations at high-risk of contracting HIV are particularly low, increasing the risk of HPV and HIV co-infection.

10 Apr 2019

New immune-based therapy eliminates HPV in one-third of women with cervical precancerous lesions

A potential new immune-based therapy to treat precancers in the cervix completely eliminated both the lesion and the underlying HPV infection in a third of women enrolled in a clinical trial.

4 Apr 2019

Tobacco use causes precancerous cells to 'fertilize' nearby cells with cancerous changes

Tobacco use causes a field of precancerous cells, increasing the risk of developing head & neck cancer. But exactly how this precancerous field influences cancer has been often overlooked.

2 Apr 2019

Imaging technique reveals differences between radiation-sensitive and treatment-resistant tumors

Researchers have started pilot clinical studies in head and neck cancer patients to determine if Raman spectroscopy, a noninvasive imaging technique, can effectively spare some patients of the toxic side effects of ineffective radiation therapy.

12 Mar 2019

Johns Hopkins study sheds light on resistance to radiation treatment

A new Johns Hopkins study offers promise towards someday being able to non-invasively examine changes in cancerous tumors to determine whether they'll respond to radiation treatment, before treatment even begins.

1 Mar 2019

Cervical cancer could be eradicated by 2100

Scaling up the human papillomavirus (HPV) vaccine could eradicate cervical cancer in high-income countries within 30 years, according to a new study.

21 Feb 2019

Regular use of aspirin may help some patients survive head and neck cancer

Regular use of aspirin or other nonsteroidal anti-inflammatory drugs may help some patients with head and neck cancer survive the disease, according to a study led by Professor Jennifer Grandis at the University of California, San Francisco.

27 Jan 2019

Regular use of common pain relief medicines improves survival for head and neck cancer patients

Regular use of a common type of medication, such as aspirin and ibuprofen, significantly improves survival for a third or more patients with head and neck cancer, a new study led by UC San Francisco has found.

25 Jan 2019

Researchers discover extent of opioid use and abuse in head and neck cancer patients

Cancer patients are often prescribed pain medications, for example during recovery from surgical procedures. However, for many cancer patients, the use of opioid pain medications during treatment can be a gateway to misuse or addiction once treatment ends.

27 Dec 2018

Researchers examine why HIV-infected patients have higher rates of cancer

AIDS patients suffer higher rates of cancer because they have fewer T-cells in their bodies to fight disease. But new research examines why HIV-infected patients have higher rates of cancer--among the leading causes of death among that population--than the general population.

5 Dec 2018

Routine mouth cancer screens could save lives

The Head and Neck Cancer Foundation is calling all Brits to ask their dentists to conduct mouth cancer screens at their next appointment. This should be routinely included within the price of a dental check-up and should take no more than one minute.

2 Nov 2018

NEC and Transgene sign MOU for strategic collaboration aimed at treating solid cancers

NEC Corporation and Transgene today announced the signing of a Memorandum of Understanding for a strategic collaboration aimed at the treatment of solid cancers.

30 Oct 2018

Head and neck cancer survivors more likely to commit suicide

Despite improved survival rates among cancer patients, the risk of death by suicide remains high, especially among those treated for head and neck cancers.

25 Oct 2018

Novel blood test shows promise for monitoring HPV-linked head and neck cancer after treatment

A new blood test developed by University of North Carolina Lineberger Comprehensive Cancer Center researchers shows promise for tracking HPV-linked head and neck cancer patients to ensure they remain cancer-free after treatment.

23 Oct 2018

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.

23 Oct 2018

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasized, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

LJI and UC San Diego awarded $ 4.5 million as part of NCI's Cancer Moonshot initiative

Researchers at La Jolla Institute for Immunology and UC San Diego have been awarded $ 4.5 million as part of the National Cancer Institute's Cancer Moonshot initiative.

19 Oct 2018

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

28 Sep 2018

Head and Neck Cancer News and Research

HPV vaccination rates are low, especially in HIV prone populations

New immune-based therapy eliminates HPV in one-third of women with cervical precancerous lesions

Tobacco use causes precancerous cells to 'fertilize' nearby cells with cancerous changes

Imaging technique reveals differences between radiation-sensitive and treatment-resistant tumors

Johns Hopkins study sheds light on resistance to radiation treatment

Cervical cancer could be eradicated by 2100

Regular use of aspirin may help some patients survive head and neck cancer

Regular use of common pain relief medicines improves survival for head and neck cancer patients

Researchers discover extent of opioid use and abuse in head and neck cancer patients

Researchers examine why HIV-infected patients have higher rates of cancer

Routine mouth cancer screens could save lives

NEC and Transgene sign MOU for strategic collaboration aimed at treating solid cancers

Head and neck cancer survivors more likely to commit suicide

Novel blood test shows promise for monitoring HPV-linked head and neck cancer after treatment

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

LJI and UC San Diego awarded $ 4.5 million as part of NCI's Cancer Moonshot initiative

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News